NYSE:NUVB

Nuvation Bio Stock Forecast, Price & News

$11.53

+0.84 (+7.86 %)

(As of 04/14/2021 03:59 PM ET)

Add

Compare

Today's Range

$11.04

Now: $11.53▼

$11.95

50-Day Range

$9.83

MA: $11.50▼

$14.57

52-Week Range

$8.56

Now: $11.53▼

$15.07

Volume27,175 shs

Average Volume821,973 shs

Market Capitalization$2.51 billion

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting CDK2, CDK4, and CDK6. It is also developing NUV-868, a selective inhibitor of the BET family of epigenetic transcriptional regulators; NUV-569, a differentiated selective inhibitor of the Wee1 kinase; NUV-1182, an adenosine receptor inhibitor; and DDC platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to androgen receptor-expressing cancer cells , as well as PARP inhibitor to ER-expressing cancer cells. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was incorporated in 2018 and is headquartered in New York, New York.

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Biotechnology

Sub-IndustryN/A

SectorMedical

Current SymbolNYSE:NUVB

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.nuvationbio.com

Phone650-245-3818

Employees36

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares217,650,000

Market Cap$2.51 billion

Next Earnings Date6/10/2021 (Estimated)

OptionableNot Optionable

Headlines

Nuvation Bio (NYSE:NUVB) Shares Gap Up Following Insider Buying Activity
April 14, 2021 | americanbankingnews.com

Oleg Nodelman Buys 133,000 Shares of Nuvation Bio Inc. (NYSE:NUVB) Stock
April 13, 2021 | americanbankingnews.com

Oleg Nodelman Acquires 300,000 Shares of Nuvation Bio Inc. (NYSE:NUVB) Stock
April 13, 2021 | americanbankingnews.com

Nuvation Bio (NYSE:NUVB) Receives New Coverage from Analysts at Royal Bank of Canada
April 13, 2021 | americanbankingnews.com

Nuvation Bio (NYSE:NUVB) Trading Up 5.3%
April 13, 2021 | americanbankingnews.com

Nuvation Bio (NYSE:NUVB) Sees Strong Trading Volume
April 8, 2021 | americanbankingnews.com

Nuvation Bio (NYSE:NUVB) Shares Down 4.3%
April 6, 2021 | americanbankingnews.com

Nuvation Bio Inc. (NYSE:NUVB) Receives Average Recommendation of "Buy" from Analysts
April 6, 2021 | americanbankingnews.com

Brokerages Expect Nuvation Bio Inc. (NYSE:NUVB) to Post -$0.08 Earnings Per Share
April 5, 2021 | americanbankingnews.com

Nuvation Bio (NYSE:NUVB) Trading Up 7.8%
April 5, 2021 | americanbankingnews.com

Nuvation Bio Reports Full Year 2020 Financial Results and Provides Business Update
March 11, 2021 | finance.yahoo.com

See More Headlines

MarketRank^™

Overall MarketRank^™

2.23 out of 5 stars

Medical Sector

93rd out of 2,019 stocks

Biotechnology Industry

9th out of 145 stocks

4.5 Analyst's Opinion

Consensus Rating
Nuvation Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $17.40, Nuvation Bio has a forecasted upside of 47.5% from its current price of $11.80.
Amount of Analyst Coverage
Nuvation Bio has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

5.0 Community Rank

Outperform Votes
Nuvation Bio has received 12 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Nuvation Bio has received 0 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Nuvation Bio has received 100.00% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Nuvation Bio and other stocks. Vote “Outperform” if you believe NUVB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NUVB will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Nuvation Bio does not currently pay a dividend.
Dividend Growth
Nuvation Bio does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Nuvation Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,271,170.00 in company stock and sold $0.00 in company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

$11.53

+0.84 (+7.86 %)

(As of 04/14/2021 03:59 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive NUVB News and Ratings via Email

Sign-up to receive the latest news and ratings for NUVB and its competitors with MarketBeat's FREE daily newsletter.

Nuvation Bio (NYSE:NUVB) Frequently Asked Questions

Is Nuvation Bio a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nuvation Bio in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Nuvation Bio stock.
View analyst ratings for Nuvation Bio or view top-rated stocks.

What stocks does MarketBeat like better than Nuvation Bio?

Wall Street analysts have given Nuvation Bio a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Nuvation Bio wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Nuvation Bio's next earnings date?

Nuvation Bio is scheduled to release its next quarterly earnings announcement on Thursday, June 10th 2021.
View our earnings forecast for Nuvation Bio.

What price target have analysts set for NUVB?

6 brokers have issued 12-month price targets for Nuvation Bio's shares. Their forecasts range from $15.00 to $20.00. On average, they expect Nuvation Bio's stock price to reach $17.40 in the next twelve months. This suggests a possible upside of 50.9% from the stock's current price.
View analysts' price targets for Nuvation Bio or view top-rated stocks among Wall Street analysts.

Who are Nuvation Bio's key executives?

Nuvation Bio's management team includes the following people:

Dr. David T. Hung M.D., Founder, Pres, CEO & Director (Age 63, Pay $1.16M)
Ms. Jennifer A. Fox, Chief Financial Officer (Age 49, Pay $557.9k)
Dr. Gary Hattersley, Chief Scientific Officer (Age 54, Pay $687.88k)
Ms. Stacy Markel, Sr. VP of HR (Age 56)
Dr. Thomas S. Templeman, Sr. VP of Pharmaceutical Operations & Quality (Age 61)
Dr. Sergey Yurasov, Chief Medical Officer (Age 52)
Dr. Lisa V. DeLuca, Sr. VP of Regulatory Affairs
Kenneth Guernsey, Sec.

Who are some of Nuvation Bio's key competitors?

Some companies that are related to Nuvation Bio include AbCellera Biologics (ABCL), Sana Biotechnology (SANA), Abcam (ABCM), Cronos Group (CRON), Seer (SEER), Genus (GNS), BTG (BTG), Abcam (ABC), MorphoSys (MOR), ImmunityBio (IBRX), BioAtla (BCAB), Immunocore (IMCR), Cullinan Oncology (CGEM), Cricut (EWTX) and Trillium Therapeutics (TRIL).
View all of NUVB's competitors.

What is Nuvation Bio's stock symbol?

Nuvation Bio trades on the New York Stock Exchange (NYSE) under the ticker symbol "NUVB."

How do I buy shares of Nuvation Bio?

Shares of NUVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nuvation Bio's stock price today?

One share of NUVB stock can currently be purchased for approximately $11.53.

How much money does Nuvation Bio make?

Nuvation Bio has a market capitalization of $2.51 billion.

How many employees does Nuvation Bio have?

Nuvation Bio employs 36 workers across the globe.

What is Nuvation Bio's official website?

The official website for Nuvation Bio is www.nuvationbio.com.

How can I contact Nuvation Bio?

The company can be reached via phone at 650-245-3818.

This page was last updated on 4/14/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Nuvation Bio Stock Forecast, Price & News

Adding

Adding

Adding Nuvation Bio Inc.

Industry, Sector and Symbol

Debt

Price-To-Earnings

Sales & Book Value

Profitability

Miscellaneous

Headlines

MarketRank™

Overall MarketRank™

4.5 Analyst's Opinion

Consensus Rating

Price Target Upside/Downside

Amount of Analyst Coverage

5.0 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment